Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Abiomed, Inc.    ABMD

ABIOMED, INC.

(ABMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Abiomed : to Hold Fireside Chat at the Stephens Annual Investment Conference 2020

11/11/2020 | 07:01am EST

Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the Stephens Annual Investment Conference 2020 (virtual) on Wednesday, November 18, 2020 at 9:00am ET.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission (the “SEC”), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


© Business Wire 2020
All news about ABIOMED, INC.
01/14ABIOMED : Third Quarter Fiscal 2021 Earnings and Conference Call Notification
BU
01/07ABIOMED : Continues to Strengthen its Intellectual Property, Now Holds More Than..
BU
01/06Artificial heartmaker Carmat to start sales after EU approval
RE
01/01ABIOMED : Significant Insider Selling in Shares of Abiomed (ABMD) Continues
MT
2020INSIDER TRENDS : Abiomed Insider Extends 90-Day Selling Trend
MT
2020Stocks End Lower After Push for Higher Stimulus Payments Stalls in Senate
MT
2020ABIOMED : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
2020ABIOMED : ABMD) sees Significant Insider Selling Continuing
MT
2020INSIDER TRENDS : Selling By Insiders Endures at Abiomed
MT
2020ABIOMED : First Patients, Including a COVID-19 Patient, Treated with Abiomed's I..
AQ
More news
Financials (USD)
Sales 2021 834 M - -
Net income 2021 207 M - -
Net cash 2021 608 M - -
P/E ratio 2021 72,6x
Yield 2021 -
Capitalization 14 899 M 14 899 M -
EV / Sales 2021 17,1x
EV / Sales 2022 14,0x
Nbr of Employees 1 536
Free-Float 92,2%
Chart ABIOMED, INC.
Duration : Period :
Abiomed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIOMED, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 326,60 $
Last Close Price 329,69 $
Spread / Highest target 13,7%
Spread / Average Target -0,94%
Spread / Lowest Target -27,8%
EPS Revisions
Managers and Directors
NameTitle
Michael R. Minogue Chairman, President & Chief Executive Officer
David M. Weber Chief Operating Officer & Senior Vice President
Todd A. Trapp Chief Financial Officer & Vice President
Thorsten Sieß Chief Technology Officer & Vice President
Charles A. Simonton Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ABIOMED, INC.1.69%14 899
THERMO FISHER SCIENTIFIC8.02%199 412
DANAHER CORPORATION6.58%168 182
INTUITIVE SURGICAL, INC.-4.85%91 508
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.3.75%82 922
SIEMENS HEALTHINEERS AG3.86%56 444